Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Margulis AV, Houben E, Hallas J, Overbeek JA, Pottegard A, Torp-Pedersen T, Perez-Gutthann S, Arana A. Ophthalmic nepafenac use in the Netherlands and Denmark. Acta Ophthalmol. 2017 Aug;95(5):509-17. doi: 10.1111/aos.13468
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Becker N, Fortuny J, Alvaro T, Nieters A, Maynadie M, Foretova L, Staines A, Brennan P, Boffetta P, Cocco PL, de Sanjose S. Medical history and risk of lymphoma: results of a European case-control study (EPILYMPH). J Cancer Res Clin Oncol. 2009 Aug;135(8):1099-107. doi: 10.1007/s00432-009-0551